Peps
What is TB-500?
TB-500 is associated with a short thymosin beta-4 fragment. Much of the biology cited in marketing instead concerns the full-length parent peptide.
Biological role or research focus
Thymosin-fragment research.
FDA identifies a thymosin beta-4 fragment under this name. Findings about full-length thymosin beta-4 do not automatically transfer.
Role reference: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗
Names you may encounter
TB 500 · TB500 · thymosin beta-4 fragment
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Thymosin beta-4-related fragment
- Main research area
- Identity and repair-mechanism research
- Evidence featured
- Related-peptide mechanistic review
- Source check
- October 4, 2026
Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗
Molecular structure
Mechanism & research rationale
Thymosin beta-4 research examines actin-related processes, cell migration, and wound responses. Different regions can have different activities; a short sequence does not inherit all parent-protein effects.
Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗
Research context & status
The linked mechanistic paper is related background, not a clinical TB-500 efficacy trial. FDA identifies the LKKTETQ fragment under this name. Exact sequence and modification must be checked before associating a study with a listing.
Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Related-peptide mechanistic review · 2010
Thymosin beta-4 active regions
Biological activities of thymosin beta4 defined by active sites in short peptide sequences.
- Population / model
- Published experimental work on full-length thymosin beta-4 and shorter sequences.
- Study design
- Structure/function synthesis discussing different active regions; not a human clinical trial.
- Main finding
- The paper discusses migration and wound-related activity associated with a sequence containing LKKTETQ, alongside other active regions of the parent protein.
- Limits & context
- This is background on related sequences, not direct clinical evidence for a marketed TB-500 preparation. It must not be presented as a human recovery trial.
Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗
Related-compound human trial · 2015
RGN-259 in severe dry eye — related molecule
What does a small full-length thymosin β4 eye-drop study actually tell us?
- Population / model
- Nine patients with severe dry eye; 12 treated eyes and six control eyes.
- Study design
- Randomized, double-masked, vehicle-controlled phase 2 trial: 28 days of treatment and follow-up to day 56.
- Main finding
- The abstract reported improvements in ocular discomfort and corneal staining at selected assessments, including day 56, with the thymosin β4 formulation.
- How to read it
- The participants are nine people, not 18 independent people. The studied preparation was RGN-259 eye drops containing full-length thymosin β4.
- Limits & context
- A very small trial with multiple assessments. It does not test a TB-500 fragment, systemic administration, tendon repair, or a seller’s vial. Related-compound evidence must not be presented as a TB-500 clinical trial.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety evidence & remaining uncertainty
FDA identifies a human-exposure data gap. Evidence about a parent protein cannot establish fragment or commercial-preparation safety.
Source: FDA · Peptide compounding safety concerns ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
Separating perceived peptide effects from changed habits
The speakers name several peptides while discussing how changes in nutrition, sleep, and training can accompany perceived benefits. This is a discussion of experience and confounding factors, not a controlled comparison.
Did a study isolate the peptide’s effect from simultaneous changes in behavior?
Caption excerpt reviewed · Claims not independently verified · 2026-10-04
Original episode: BURN FAT FASTER WITH MOTS C | Josh Holyfield | Real Bodybuilding Podcast
Watch the source discussions
36 matching video records · 15 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Fouad Abiad Media
BURN FAT FASTER WITH MOTS C | Josh Holyfield | Real Bodybuilding Podcast ↗
Captions indexed · Automatic matches need review
Fouad Abiad Media
RETATRUTIDE: EVERYTHING YOU NEED TO KNOW | Wes Christensen | Fouad Abiad's Real Bodybuilding Podcast ↗
Captions indexed · Automatic matches need review
Mind Pump Show
Breakthrough Muscle Building Peptides with Jay Campbell | Mind Pump 2840 ↗
Captions indexed · Automatic matches need review
Mind Pump Show
Hormones, Peptides & Body Transformation with Phil Vella CEO of Vita Bella Health | Mind Pump 2882 ↗
Captions indexed · Automatic matches need review
Mind Pump Show
Peptides vs Bioregulators: The Future of Health Optimization w/ Nick Andrews | Mind Pump 2672 ↗
Captions indexed · Automatic matches need review
Peptide Of The Week
Peptide of the Week: Gut Health Deep Dive With Liz Roman, The Poop Queen ↗
Captions indexed · Automatic matches need review
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
TB-500 (10mg)
BioLongevity Labs · Vendor-labeled research use only
$164.97
Listed in stock · Snapshot 2026-10-04
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
BPC-157 TB-500 Blend (10mg)
BioLongevity Labs · Vendor-labeled research use only
$119.97
Listed in stock · Snapshot 2026-10-04
Options may vary. Shipping and tax excluded.
Blend ingredients & evidence →
View seller listing ↗Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
GLOW Blend (BPC-157 TB-500 GHK-CU) (70mg)
BioLongevity Labs · Vendor-labeled research use only
$259.97
Listed in stock · Snapshot 2026-10-04
Options may vary. Shipping and tax excluded.
Blend ingredients & evidence →
View seller listing ↗Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
KLOW Blend (GHK-Cu, BPC-157, TB-500, KPV) 80mg
BioLongevity Labs · Vendor-labeled research use only
$274.97
Listed in stock · Snapshot 2026-10-04
Options may vary. Shipping and tax excluded.
Blend ingredients & evidence →
View seller listing ↗Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
Regeno Blend (BPC-157, TB-500, Cartalax) 30mg
BioLongevity Labs · Vendor-labeled research use only
$279.97
Listed in stock · Snapshot 2026-10-04
Options may vary. Shipping and tax excluded.
Blend ingredients & evidence →
View seller listing ↗Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
TB-500 (10 mg)
American Peptides · Vendor-labeled research use only
$100.00
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
BPC-157 + TB-500 (20 mg)
American Peptides · Vendor-labeled research use only
$195.00
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
TB-500 (5 mg / 10 mg)
PSPeptides · Vendor-labeled research use only
$44.99–$79.99
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
BPC-157 + TB-500 blend (20 mg (10+10 mg) / 10 mg (5+5 mg))
PSPeptides · Vendor-labeled research use only
$59.99–$79.99
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- FDA identifies a thymosin beta-4 fragment under this name. Findings about full-length thymosin beta-4 do not automatically transfer.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is full-length thymosin beta-4 the same as TB-500 fragment?
No. This distinction can determine whether the entire cited evidence is relevant.
Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗
Is there a direct human recovery trial on this page?
No. The selected publication is mechanistic background and is labeled accordingly; it should not be read as proof of clinical recovery.
Source: Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗
What does the additional research establish?
The participants are nine people, not 18 independent people. The studied preparation was RGN-259 eye drops containing full-length thymosin β4. A very small trial with multiple assessments. It does not test a TB-500 fragment, systemic administration, tendon repair, or a seller’s vial. Related-compound evidence must not be presented as a TB-500 clinical trial.
References & editorial record
- FDA · Compounding safety concerns ↗
- Biological activities of thymosin beta4 defined by active sites in short peptide sequences. ↗
- G Sosne and colleagues · Cornea · 2015 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
BPC-157 vs TB-500: compare the research, not the reputation
Tendon models, fragment identity, and a tiny eye-drop trial answer different questions. Here is how to keep them separate.
Read the guide →RESEARCH FIELD GUIDE
TB-500 vs thymosin beta-4: a fragment is not the whole protein
TB-500 and thymosin beta-4 are often used as if they were the same thing. They are not, and most of the human research involves the full protein, not the fragment sold as TB-500.
Read the guide →